|
 The drug can now be used to treat patients with subtypes of chronic
hepatitis C virus (HCV) and patients who are co-infected with Human
Immunodeficiency Virus (HIV), Gilead said in a statement.
The once-daily pill, used in combination with antiviral ribavirin,
was also approved to be used for 12 weeks as an alternate therapy to
Harvoni alone, which is used for 24 weeks to treat patients with
cirrhosis.
Results from the study showed that about 93 percent of the patients
with subtypes of the virus and 96 percent of patients co-infected
with HIV showed a sustained response to the virus within 12 weeks of
treatment.
Sustained viral response is the term for a successful hepatitis C
treatment outcome. It means that hepatitis-C virus is undetectable
for 12 or more weeks after the end of treatment.
Gilead's blockbuster Harvoni was first approved by the FDA in
October 2014. The drug had sales of about $3.3 billion in the latest
quarter ended Sept 30.
Hepatitis C, estimated to infect about 3.2 million Americans, is a
viral disease that causes inflammation of the liver that can lead to
liver failure.
[to top of second column] |
Patients with HCV and HIV co-infection represent about 30 percent of
the total HIV-infected population in the United States, Gilead says.
Gilead's shares were little changed in the after-market trading.
(Reporting by Rosmi Shaji in Bengaluru; Editing by Anil D'Silva and
Ken Wills)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
